Kimberly Clark (KMB) Launches Arbex Venture, Is The Recent Rally Already Priced In?

Kimberly-Clark (KMB) has been in focus after launching Arbex, a US$3.4b joint venture with Suzano that includes divesting its International Family Care & Professional division and licensing key tissue brands globally.

See our latest analysis for Kimberly-Clark.

Those Arbex headlines and recent index changes have coincided with a sharp shift in sentiment, with Kimberly-Clark’s share price delivering a 15.83% 1 month return and 18.28% 3 month return, even though the 1 year total shareholder return is down 8.92%.

If Kimberly-Clark’s recent move has you reassessing your watchlist, it could be a good time to look across the market and see what stands out in 20 top founder-led companies

With Kimberly-Clark now trading close to the latest analyst price target and sitting on an estimated 29% intrinsic discount, investors have to ask: is the recent rally leaving value on the table, or is the market already pricing in the next leg of growth?

Most Popular Narrative: 0% Overvalued

Kimberly-Clark’s most followed narrative pegs fair value at about $114.67, almost identical to the last close at $114.72, which puts every assumption under the microscope.

Disciplined cost management (including targeted SG&A savings, productivity initiatives delivering 5%–6% of COGS, and digital/automation investments) is enhancing operating efficiency, providing earnings and margin tailwinds that support attainment of multi-year gross margin and operating profit milestones.

Read the complete narrative.

Curious what earnings profile supports a fair value so close to today’s price? The narrative leans heavily on steadier growth, rising margins and a lower future earnings multiple. The full set of assumptions matters.

Result: Fair Value of $114.67 (ABOUT RIGHT)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Kimberly-Clark’s story can shift quickly if private labels pressure pricing or if weaker consumer demand limits the volume growth that this narrative depends on.

Find out about the key risks to this Kimberly-Clark narrative.

Another View: Kimberly-Clark Through The SWS DCF Lens

While the popular narrative sees Kimberly-Clark trading close to fair value at about $114.67, the SWS DCF model paints a very different picture. It shows an estimate of future cash flow value around $162.18 per share, implying the stock trades at roughly a 29% discount. That raises a simple question for investors: which story do you trust more?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Kimberly-Clark for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment around Kimberly-Clark clearly split between opportunity and caution, it makes sense to move quickly, test the assumptions and weigh both sides of the story using the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Kimberly-Clark?

If Kimberly-Clark is already on your radar, do not stop there. Use the Simply Wall Street Screener to uncover fresh ideas that fit your portfolio preferences.

• Target steady compounding by scanning companies with consistent cash generation and conservative finances using the solid balance sheet and fundamentals stocks screener (47 results).
• Hunt for potential mispricings by sorting through companies that look attractively valued on quality and fundamentals in the screener containing 18 high quality undiscovered gems.
• Strengthen your income stream by focusing on companies with higher yields and resilient payout profiles through the 7 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com